In a patient with severe rheumatic mitral regurgitation and severe aortic regurgitation, can medical management alone be sufficient treatment?

Medical Management Alone is NOT Sufficient for Severe Rheumatic MR and AR

In a patient with severe rheumatic mitral regurgitation and severe aortic regurgitation, medical management alone is inadequate—surgical intervention is indicated for both valves, with the goal of repairing or replacing them to prevent irreversible left ventricular dysfunction, heart failure, and death. 1

Why Surgery is Mandatory

The 2017 ESC/EACTS guidelines are unequivocal: surgery is indicated for severe primary mitral regurgitation in symptomatic patients with LVEF >30% (Class I, Level B) and in asymptomatic patients with LV dysfunction (LVESD ≥45 mm and/or LVEF ≤60%) (Class I, Level B) 1. These are not suggestions—they are Class I recommendations based on mortality and morbidity data.

For severe aortic regurgitation, while the provided guideline excerpt doesn't detail AR-specific indications as explicitly, the clinical reality is clear: severe AR leads to progressive LV dilatation and dysfunction, and once symptoms or LV dysfunction develop, outcomes deteriorate rapidly without surgery 2. Medical therapy with vasodilators may temporize but should not replace or delay aortic valve surgery when indicated 2.

The Rheumatic Context Changes Nothing—It Makes Surgery More Urgent

Rheumatic heart disease typically affects multiple valves simultaneously. When you have both severe MR and severe AR, you're dealing with combined volume overload that accelerates LV dysfunction. The research confirms that in combined mitral and aortic valve disease, it is critical to assess both valves carefully and attempt repair of one or both valves, avoiding double valve replacement when possible 3.

A recent 2026 study specifically addressing moderate AR in rheumatic mitral valve surgery found that concurrent aortic valve replacement significantly improves outcomes without increasing surgical risk 4. If this is true for moderate AR, the case for intervention is even stronger with severe AR.

Medical Management: A Bridge, Not a Destination

Medical therapy (diuretics, ACE inhibitors, vasodilators, digoxin) can:

• Reduce preload and afterload
• Diminish regurgitant volume temporarily
• Improve symptoms in the short term

However, there is no convincing evidence that medical treatment improves symptom status or favorably affects natural history over years 5. The yearly mortality with medical treatment alone in severe organic MR is approximately 6% in patients aged 50 years or older 6, and this compounds with severe AR.

The Timing Algorithm

Operate when ANY of these are present:

1. Symptomatic (dyspnea, fatigue, heart failure)—Class I indication 1
2. Asymptomatic with LV dysfunction:
   • LVEF ≤60% OR
   • LVESD ≥45 mm (or indexed LVESD if using newer metrics) 1
3. Severe LV dilatation (end-diastolic dimension >8 cm or end-systolic dimension >5.5 cm) 5
4. End-systolic stress/volume index ≤2.2 (predicts poor postoperative outcomes—operate before reaching this point) 5

Do NOT wait for:

• LVEF to drop below 30% (too late—poor surgical outcomes)
• Severe symptoms (irreversible myocardial damage may have occurred)
• Pulmonary hypertension to become fixed

Surgical Strategy for Combined Disease

Mitral valve repair should be the preferred technique when durable results are expected (Class I, Level C) 1. For rheumatic disease, repair may be more challenging than degenerative disease, but it should still be attempted.

For the aortic valve in rheumatic disease, repair is not yet well established 3, so replacement is typically necessary.

The goal: repair the mitral valve if possible, replace the aortic valve, and avoid double valve replacement if you can salvage one valve 3.

Common Pitfalls to Avoid

1. Delaying surgery because the patient is "stable" on medical therapy—LV remodeling is progressive and may become irreversible
2. Waiting for symptoms—by the time severe symptoms appear, LV dysfunction may be irreversible 6
3. Assuming rheumatic disease means poor surgical outcomes—modern surgical techniques have excellent results when performed before advanced LV dysfunction
4. Ignoring the aortic valve because you're focused on the mitral valve—both need addressing in the same operation 4

The Bottom Line

Medical management alone in severe rheumatic MR + severe AR is palliative at best and negligent at worst. These patients need surgical evaluation urgently. Valve repair improves outcome compared with replacement and reduces mortality by approximately 70% in severe organic MR 6. The best results occur in asymptomatic patients operated on in advanced repair centers with low operative mortality (<1%) and high repair rates (≥80-90%) 6.

Refer to a Heart Valve Center immediately for surgical evaluation—medical management is only appropriate while awaiting surgery or in patients with prohibitive surgical risk 1.